Medical Xpress October 1, 2021
Tanner Stening, Northeastern University

With new COVID-19 cases remaining at high levels across the U.S., new drug therapies that may help people who contract the respiratory disease evade serious illness are starting to garner more attention.

The World Health Organization recently endorsed an antibody cocktail made by Regeneron Pharmaceuticals, a combination drug that has been used widely to bolster by infusing them with designed to combat COVID. And a new antiviral pill that could be taken daily, called molnupiravir, is being studied as a way of halting COVID illness early in its course.

While these treatments for COVID have helped to shore up hospital resources by preventing severe illness in many patients, they are far from a silver bullet, and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article